文献速递神经技术与安全MR

对比剂特异性参数优化用于T1加权快速扰相梯度回波成像:1.5T和3.0T下钆特酸葡甲胺与钆布醇的应用实例

Contrast Agent-Specific Parameter Optimization for T 1 -Weighted Fast Spoiled Gradient Echo Imaging : Use Cases for Gadoterate Meglumine and Gadobutrol at 1.5T and 3.0T.
PubMed 文献 · Invest Radiol · 2025-11-01

本研究基于钆特酸葡甲胺与钆布醇的弛豫率差异,推导快速扰相梯度回波序列信号方程,模拟1.5T和3.0T下最佳翻转角与重复时间组合,理论对比增益为24%-28%;2例脑部增强MRI在体验证显示,优化参数较厂商默认设置对比增益为19%-44%(弥漫强化病灶)和91%(弱强化局灶病灶)。

要点

  • 优化翻转角和重复时间可提高病灶与健康组织间的对比度。
  • 理论模拟显示优化参数可带来24%-28%的对比增益。
  • 在体2例脑部增强MRI显示对比增益为19%-44%和91%。

核心结论

  • 使用所提框架推导的调整后重复时间和翻转角值改善了健康与病变组织间的图像对比度,增强了异常的可视化;该方法可用于优化常规临床MRI协议并平衡扫描时间与对比增强,可能转化为更精确的病灶检测,从而可能实现更早、更准确的诊断或治疗监测。

研究设计与样本

  • 研究推导了快速扰相梯度回波序列在非强化和强化组织中的信号方程,使用钆特酸葡甲胺和钆布醇,在1.5T和3.0T两个场强下进行模拟,考虑T1比值1.1至1.8的假设病灶及不同自旋密度和场强依赖的组织弛豫时间变化;在2例接受脑部增强MRI的患者中进行了在体验证。

关键影像表现/征象

  • 使对比强化病灶信号强度最大化的翻转角(Ernst角)不同于未增强MRI中使病灶与健康组织间T1依赖对比最大化的翻转角(Pelc角),也不同于增强MRI中使同一对比最大化的翻转角。
  • 理论模拟显示使用优化参数可能获得24%-28%的对比增益。
  • 在体采集显示,与厂商默认设置相比,优化采集参数对弥漫强化病灶的对比增益为19%-44%,对弱强化局灶病灶的对比增益为91%。

临床应用与阅片要点

  • 作者认为,该框架推导的调整后重复时间和翻转角值可改善健康与病变组织间的图像对比度,增强异常的可视化。
  • 作者认为,该方法可用于优化常规临床MRI协议并平衡扫描时间与对比增强。
  • 作者认为,这可能转化为更精确的病灶检测,从而可能实现更早、更准确的诊断或治疗监测。

局限性

  • 在体验证仅纳入2例患者。
  • 作者指出该结果可能转化为更精确的病灶检测,可能实现更早、更准确的诊断或治疗监测(原文用「may translate」「potentially leading to」等限定语气)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: The objective of this study is to derive a contrast agent-specific theoretical framework to optimize acquisition parameters for contrast-enhanced magnetic resonance imaging (MRI) based on the physiochemical properties of gadolinium-based contrast agents, focusing on fast spoiled gradient recalled echo sequences. The goal is to enhance the lesion-to-background contrast for improved diagnostic sensitivity in clinical applications.

MATERIALS AND METHODS: Signal equations for fast spoiled gradient recalled echo sequences were derived for nonenhancing and enhancing tissues using gadoterate meglumine and gadobutrol, characterized by distinct longitudinal (r 1 ) and transverse (r 2 /r* 2 ) relaxivities. Simulations were conducted at 2 field strengths, 1.5T and 3.0T, and various scenarios were considered, including hypothetical lesions with T 1 ratios ranging from 1.1 to 1.8. The signal behavior was analyzed across a range of initial conditions, including different spin densities and field-strength dependent variations in tissue relaxation times. The optimal flip angle and repetition time combinations were determined to maximize contrast. In vivo validation was performed on 2 patients undergoing contrast-enhanced MRI of the brain, using the proposed acquisition parameters.

RESULTS: The modeling and simulations revealed that the flip angle that maximizes signal intensity for a contrast-enhancing lesion (Ernst angle) differs from the flip angle that maximizes T 1 -dependent contrast between lesion and healthy tissue in unenhanced MRI (Pelc angle) and also differs from the flip angle that maximizes the same in contrast-enhanced MRI. The theoretical simulations indicated possible contrast gains of 24%-28% using optimized parameters. The in vivo acquisitions demonstrated contrast gains of 19%-44% for a diffuse enhancing lesion and 91% for a weakly enhancing focal lesion, when comparing the optimized acquisition parameters to manufacturer's default settings.

CONCLUSIONS: Adjusted repetition time and flip angle values, derived using the proposed framework, improved the image contrast between healthy and diseased tissues, enhancing the visualization of abnormalities. This approach can be used to optimize routine clinical MRI protocols and balance scan time with contrast enhancement. This may translate to more precise lesion detection, potentially leading to earlier and more accurate diagnosis or treatment monitoring in clinical practice.

来源:Invest Radiol,查看原文。版权归原作者所有。

引用

  1. Gkotsis DE, Bherwani A, Kapsalaki EZ, et al. Contrast Agent-Specific Parameter Optimization for T 1 -Weighted Fast Spoiled Gradient Echo Imaging : Use Cases for Gadoterate Meglumine and Gadobutrol at 1.5T and 3.0T. Invest Radiol. 2025. PMID: 40328243. doi:10.1097/RLI.0000000000001205

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。